Standard Glass Lining Technology
MainboardNSE₹410 Cr issue
+25.71%
Listing gain over issue price
Issue size
₹410 Cr
1 lot at cut-off
₹14,980
Lot size
107shares
Open
06 Jan 2025
Close
08 Jan 2025
Allotment
09 Jan 2025
Listing
13 Jan 2025
Listing performance
Issue price
₹140
Listed at
₹176
Listing-day close
₹163.35
Latest price
₹334.20
Close on 23 Oct 2026
Listing gain
+25.71%
Return since issue
+138.71%
Scheduled dates
Tentative timetable — a past date is not confirmation the step completed
Issue details
- IPO date
- 06 Jan 2025 – 08 Jan 2025
- Listing date
- 13 Jan 2025
- Face value
- ₹10 per share
- Issue price
- ₹140 per share
- Lot size
- 107 shares
- Listing at
- NSE
- Total issue size
- ₹410 Cr
- Market cap at offer price
- ₹2,793 Cr
- Promoter holding
- 72.49% → 67.04% pre-issue → post-issue
- ISIN
- INE0M4D01010
- Registrar
- Kfin Technologies Ltd.
- Lead managers
- IIFL Capital Services Ltd.
- Registered office
- 10th Floor, PNR High Nest, Hydernagar, KPHB Colony, Telangana
Reservation and application size
How the issue is split between investor categories, and what each may bid
| Investor category | Shares | % of net | % of total |
|---|---|---|---|
| Anchor investor · within QIB | 87,86,009 | — | — |
| Market maker | 0 | — | — |
Application size
Minimum 107 shares per lot, in multiples, at ₹140
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 107 | ₹14,980 |
| Retail (max) | 13 | 1,391 | ₹1,94,740 |
| S-HNI (min) | 14 | 1,498 | ₹2,09,720 |
| S-HNI (max) | 66 | 7,062 | ₹9,88,680 |
| B-HNI (min) | 67 | 7,169 | ₹10,03,660 |
Category limits
| Category | Bid size | Cut-off |
|---|---|---|
| Retail (RII) | Up to ₹2 lakh | Yes |
| Small HNI (sNII) | ₹2 lakh – ₹10 lakh | No |
| Big HNI (bNII) | Above ₹10 lakh | No |
| Employee | Up to ₹5 lakh | Yes |
Bidding at cut-off means accepting the final issue price without naming one. Only retail and employee applicants may do so.
Anchor investors
Institutional allocation placed a day before the issue opens, carved out of the QIB portion and locked in after listing.
Shares allocated
87,86,009
Anchor portion
₹123 Cr
at ₹140 per share
Valuation and performance
Valuation at offer price
₹140 per share
| Metric | Pre-issue | Post-issue |
|---|---|---|
| EPS (₹) | 3.25 | 3.64 |
| P/E (×) | 43.08 | 38.46 |
| Price to book (×) | 5.70 | — |
| Market cap | — | ₹2,793 Cr |
Key performance indicators
Latest reported period
- Return on net worth
- 20.74%
- ROCE
- 25.49%
- Debt / equity
- 0.32
- PAT margin
- 10.92%
- NAV per share
- ₹24.55
- Price to book
- 5.70
Single period as reported. Year-on-year movement is in the financials table below, where every period is published.
About Standard Glass Lining Technology
Standard Glass Lining Technology Limited (SGL) was incorporated as a private limited company in September 2012 and converted to a public limited company in June 2022. Based in Hyderabad, Telangana, the company is one of the top five specialised engineering equipment manufacturers for pharmaceutical and chemical sectors in India in terms of revenue in Fiscal 2024. The company offers design, engineering, manufacturing, assembly, installation and commissioning solutions on a turnkey basis. The business is driven by glass lining technology which protects contained media from exposure to water, chemicals, alkalis, and corrosion. The company generates revenue through the design and manufacture of specialized industrial process equipment, including glass-lined equipment (GLE) and related machinery, serving customers in the pharma, chemicals and food processing sectors across India.
Company Analysis
from RHPStandard Glass Lining Technology Limited is a specialized engineering equipment manufacturer for the pharmaceutical and chemical sectors in India, with in-house design, engineering, manufacturing, assembly, installation and commissioning capabilities.
Standard Glass Lining Technology Limited (SGL) was incorporated as a private limited company in September 2012 and converted to a public limited company in June 2022. Based in Hyderabad, Telangana, the company is one of the top five specialised engineering equipment manufacturers for pharmaceutical and chemical sectors in India in terms of revenue in Fiscal 2024. The company offers design, engineering, manufacturing, assembly, installation and commissioning solutions on a turnkey basis. The business is driven by glass lining technology which protects contained media from exposure to water, chemicals, alkalis, and corrosion. The company generates revenue through the design and manufacture of specialized industrial process equipment, including glass-lined equipment (GLE) and related machinery, serving customers in the pharma, chemicals and food processing sectors across India.
Specialized industrial process equipment manufacturingGlass-lined equipment (GLE) manufacturingPharmaceutical sector equipmentChemical sector equipmentFood processing sector equipment
Objects of the Issue
- Funding of capital expenditure requirements of our Company towards purchase of machinery and equipment ₹100.00 million p.29
- Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company and investment in our wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by S2 Engineering Industry Private Limited, from banks and financial institutions ₹1,300.00 million p.29
- Investment in our wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for funding its capital expenditure requirements towards purchase of machinery and equipment ₹300.00 million p.30
- Funding inorganic growth through strategic investments and/or acquisitions ₹200.00 million p.30
- General Corporate Purposes p.30
- Funding of capital expenditure requirements of our Company towards purchase of machinery and equipment p.94
- Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company and investment in our wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by S2 Engineering Industry Private Limited ₹ 1,300.00 million p.89
- Investment in our wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for funding its capital expenditure requirements towards purchase of machinery and equipment ₹ 400.00 million p.88
- Funding inorganic growth through strategic investments and/or acquisitions p.95
- General corporate purposes p.95
- Funding of capital expenditure requirements of our Company towards purchase of machinery and equipment ₹ 100.00 million p.159
- Repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by our Company and investment in our wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for repayment or prepayment, in full or in part, of all or a portion of certain outstanding borrowings availed by S2 Engineering Industry Private Limited, from banks and financial institutions ₹ 1,300.00 million p.159
- Investment in our wholly owned Material Subsidiary, S2 Engineering Industry Private Limited, for funding its capital expenditure requirements towards purchase of machinery and equipment ₹ 300.00 million p.159
- Funding inorganic growth through strategic investments and/or acquisitions ₹ 200.00 million p.159
- General corporate purposes p.159
- Expansion of existing manufacturing units and upcoming facilities through funding of capital expenditure for purchase of machinery and equipment Up to ₹400.00 million p.290
- Funding capex for new manufacturing facility and expansion
Issue Structure
- Total Issue
- Up to [●] Equity Shares of face value ₹10 each, aggregating up to ₹ [●] million
- Fresh Issue
- Up to [●] Equity Shares of face value ₹10 each, aggregating up to ₹2,100.00 million
- Offer for Sale
- Up to 14,289,367 Equity Shares of face value ₹10 each, aggregating up to ₹ [●] million by the Selling Shareholders
- Price Band
- [●] per Equity Share (Floor Price: [●]; Cap Price: [●])
- Lot Size
- [●] Equity Shares
- Face Value
- ₹10 each
Business Model
The company manufactures and sells specialized engineering equipment, particularly glass-lined equipment (GLE) and related machinery for pharmaceutical and chemical industries. Revenue is generated through the sale of designed and manufactured equipment, which includes engineering, manufacturing, assembly, installation and commissioning services on a turnkey basis. In Fiscal 2024, more than 88.20% of revenue from operations were derived from the pharmaceutical and chemical sectors combined.
Business Segments
Design, engineering, manufacturing, assembly, installation and commissioning of specialized engineering equipment, particularly glass-lined equipment for pharmaceutical and chemical industries
Manufacturing and sale of glass-lined equipment, stainless steel and nickel alloy-based process equipment for pharmaceutical manufacturers
Manufacturing and sale of glass-lined equipment, stainless steel and nickel alloy-based process equipment for chemical manufacturers
Manufacturing and sale of process equipment for paint, biotechnology, food and beverages and other industries
Manufacturing of dryers, filters, heat exchangers/condensors, reactors, distillation columns, evaporators, single fluid heating and cooling systems, blenders and mixers
Manufacturing, supply, installation, repair and service of PTFE pipes, PTFE chemical, pharma and food processing industry equipment
Manufacturing agitated mustche filter dryer, nickel alloy equipment, reactors, columns, heat exchangers, storage tanks, receivers and related equipment used in pharmaceutical or chemical industries
Glass-lined and stainless steel reactors used in pharmaceutical and chemical manufacturing for controlled chemical reactions; capacity ranges 30 litres to 40,000 litres; manufacturing capacity ~300-350 equipment per month across product portfolio; up to 100 reactors per month from specialized facility
Glass-lined storage tanks, receivers, separation equipment (ANFD - Agitated Nutsche Filter Dryers), and drying systems; includes equipment for vacuum distillation, solvent recovery, and gas dispersion processes
Turnkey facility design and commissioning solutions; PTFE lined pipes and fittings (9,000 units/month capacity); specialized accessories for glass-lined equipment; design, engineering, manufacturing, assembly, installation and commissioning solutions of pharmaceutical and chemical facilities
Includes heat transfer systems (columns, condensers, shell & tube heat exchangers, box heat exchangers, distillation columns, evaporators), pipes and fittings (PTFE lined), pumps (multistage dry claw type, lobe and claw type, oil sealed rotary vane, scroll type, roots booster), and reactors (glass-lined and stainless steel)
Includes filtration and drying equipment, storage tanks, and vessels used for separation and drying processes in pharmaceutical and chemical manufacturing
Includes design services, engineering, utility systems, installation and commissioning solutions provided on a turnkey basis for pharmaceutical and chemical manufacturing facilities
Manufactures ANFD (Agitated Nutsche Filter-Dryer), Nutsche filters, Vacuum Tray Dryers (VTD), RCVD (Roto Cone Vacuum Dryer), Tray Dryers, and Paddle Dryers for solid-liquid separation and drying of wet cakes or slurries in batch processes.
Manufactures glass-lined reactors, receivers, heat exchangers, and equipment fittings used in chemical synthesis, pharmaceutical production, and various industrial processes requiring corrosion resistance.
Manufactures storage tanks, receivers, silos, and blenders used to store liquids, solids, or gases at atmospheric or low pressures, and to combine materials in various industries.
Manufactures heat transfer devices including column, condenser, shell and tube heat exchangers and box heat exchangers used for cooling and heating in API and chemical manufacturing processes.
Manufactures mild steel or stainless steel pipes lined with polytetrafluoroethylene (PTFE) for connecting equipment and transportation of corrosive fluids in manufacturing processes, capable of withstanding temperatures up to 200°C.
Supplies and services vacuum pumps used to remove gas molecules or air particles from sealed volumes to achieve partial vacuum, enabling distillation at lower temperatures and increasing drying rates.
Provides turn-key execution of API and chemical projects involving project managing construction of facilities, installation of equipment, and commissioning including coordination, procurement, and qualification.
Manufacturing and selling of glass-lined reactors, receivers and storage tanks for the pharmaceutical industry sector
Manufacturing and selling of stainless steel and nickel/alloy steel reactors, filters, dryers, vessels, and storage tanks for the pharmaceutical industry sector
Manufacturing and selling of PTFE lined metal pipes, PTFE fittings, valves and other equipments, fittings, instruments and accessories thereof
Manufacturing of glass-lined reactors and related equipment
Manufacturing of metal equipment including stainless steel, nickel/alloy steel reactors, filters, dryers, vessels, storage tanks and vacuum pumps
Manufacturing of polytetrafluoroethylene (PTFE) lined equipment
Manufacture and sale of glass-lined shell and tube heat exchangers, reactors, agitators, storage tanks, and PTFE-lined pipes and fittings
Provision of annual maintenance contracts and comprehensive maintenance contracts for equipment and machinery
SWOT Analysis
Strengths
- • Top five specialized equipment manufacturer for pharma and chemicals in India(p.28)
- • Full-service capabilities from design to commissioning on turnkey basis(p.28)
- • Glass-lined equipment offers corrosion resistance and durability across industries(p.28)
- • Geographic proximity to pharma hub reduces supply chain costs and transportation overhead(p.63)
- • Top 3 manufacturer position in glass-lined, stainless steel and nickel alloy equipment(p.78)
- • Diverse product portfolio serving multiple industries beyond pharmaceuticals(p.77)
- • Strong repeat customer base generating majority of revenue(p.76)
- • Significant market position in glass-lined equipment manufacturing with established customer base(p.109)
- • Recent strategic acquisitions expanding product portfolio and customer reach(p.171)
- • Strong financial performance with growing revenue trajectory(p.116)
- • Top-5 specialised engineering equipment manufacturer for pharma/chemical sectors with in-house capabilities across entire value chain(p.180)
- • One of top-3 manufacturers of glass-lined, stainless steel, and nickel alloy equipment in India by revenue (FY2024)(p.180)
- • Comprehensive product portfolio of 65+ offerings across pharma/chemical value chain(p.180)
- • Strategically located in Hyderabad (Pharma Hub) with 8 facilities covering 400,000+ sq ft(p.180)
- • Advanced manufacturing capabilities: 300-350 equipment/month capacity, 100 reactors/month, 30 ANFDs/month, 9,000 PTFE pipes/month(p.180)
- • Long-standing relationships with 347 customers including marquee pharma companies; 13 of top-20 customers have relationships exceeding 3 years(p.181)
- • 50.45% revenue CAGR (FY2022-FY2024); supplied 11,000+ equipment in 10 years of operations(p.181)
- • Experienced promoters with 20+ years in pharma/chemicals specialised engineering equipment industry(p.180)
- • Established manufacturing expertise with long operational history(p.361)
- • Diversified revenue base across product lines and geographies(p.388)
- • Experienced management team with pharma sector background(p.361)
- • Top five specialized equipment manufacturer for pharma/chemical sectors in India with in-house capabilities across entire value chain(p.445)
- • Diversified customer base including 30 of ~80 pharma/chemical companies in NSE 500 index(p.446)
- • Fastest-growing company in the industry during past three completed fiscals in terms of revenue(p.445)
- • Over 11,000 products supplied over the last decade demonstrating established manufacturing capability(p.445)
- • Strategic location in Hyderabad which accounted for 40% of total Indian bulk drug production in Fiscal 2024(p.446)
- • Strong financial performance with revenue CAGR of 50.45% over 2 years and EBITDA margin of 20.09% in H1 FY2025(p.448)
- • Diversified product portfolio and revenue streams(p.465)
- • Strong organic growth and capacity expansion through acquisitions(p.467)
- • Robust profitability with double-digit growth trajectory(p.468)
- • Strong revenue growth momentum(p.467)
- • Expansion into maintenance services segment(p.467)
Weaknesses
- • Complete geographic concentration of manufacturing in Telangana(p.33)
- • Dependence on skilled labor and workforce availability(p.33)
- • Dependence on limited number of key suppliers(p.33)
- • Limited customer base with majority from pharma and chemicals(p.33)
- • History of negative cash flow from operating activities(p.33)
- • High debt levels and exposure to variable interest rates(p.34)
- • Under-utilization of manufacturing capacity(p.33)
- • One promoter and two senior management unable to trace educational documents(p.34)
- • Geographically concentrated manufacturing in single state exposes to regional risks(p.63)
- • High dependence on limited number of top customers for revenue(p.76)
- • Significant working capital requirements with long receivables cycle(p.72)
- • Dependence on limited number of key raw material suppliers(p.66)
- • Delayed statutory dues payments in past (Fiscal 2022)(p.92)
- • Corporate logo not registered and faced objections(p.73)
- • Unregistered land leases for all manufacturing facilities and registered office(p.86)
- • High debt levels requiring substantial repayment from IPO proceeds(p.163)
- • Concentration of shareholding among promoters limiting public holding(p.145)
- • Working capital dependency with significant inventory and receivables(p.114)
- • Significant dependence on chemical and pharmaceutical end-user sectors for revenue(p.71)
- • Customer concentration: top 20 customers represented significant portion of revenue(p.71)
- • High debt-to-equity ratio of 0.39 (Sept 2024); 0.32 (FY2024)(p.184)
- • Decline in ROE from 47.56% (FY2023) to 20.74% (FY2024) and 8.06% (Sept 2024)(p.184)
- • Limited geographic diversification; operations concentrated in Hyderabad(p.180)
- • High dependence on working capital borrowings for operations(p.403)
- • Significant proportion of receivables aged beyond 6 months(p.398)
- • Key personnel with missing educational documentation(p.361)
- • High inventory levels relative to revenue(p.397)
- • Dependence on limited number of key customers for significant portion of revenue(p.451)
- • Dependence on limited number of suppliers for key raw materials(p.451)
- • Land allotted by TSIIC not registered in company name; pending approvals for manufacturing facility construction(p.437)
- • Absence of long-term supply contracts exposes company to raw material price volatility(p.450)
- • Employee benefit expenses increasing as percentage of revenue(p.451)
- • High working capital intensity affecting cash flows(p.471)
- • Significant increase in working capital requirements and negative operating cash flow(p.471)
- • Substantial increase in current borrowings(p.470)
- • Dependence on limited number of suppliers for key raw materials(p.476)
- • Dependence on limited number of customers(p.476)
Opportunities
- • Strong industry growth trajectory with 10.1% CAGR forecast(p.28)
- • Global glass-lined equipment market expansion to $3.4 billion by 2028(p.28)
- • Corrosion-resistant properties enable broad industrial application(p.28)
- • Inorganic growth through acquisitions and strategic investments planned(p.30)
- • Strategic expansion into international markets leveraging existing capabilities(p.77)
- • Growth through strategic acquisitions and alliances(p.83)
- • Expansion of product portfolio into additional end-user industries(p.83)
- • Capacity expansion through new manufacturing plants(p.83)
- • Substantial market growth in glass-lined equipment sector(p.161)
- • Capacity expansion planned to capture growing pharmaceutical and chemical sector demand(p.161)
- • Strategic inorganic growth through acquisitions and investments(p.171)
- • Geographic and product diversification through subsidiary expansion(p.169)
- • Growing pharmaceutical sector projected to expand at 9.5% CAGR (FY2023-FY2028)(p.205)
- • Indian specialty chemicals expected to grow at 11.2% CAGR (FY2019-20 to FY2026-27)(p.207)
- • China+1 strategy driving shift in manufacturing to India; chemical market benefiting from China's higher costs and stricter regulations(p.207)
- • India Glass Lined Equipment (GLE) market projected to grow 10.1% CAGR (FY2024-2029) to INR 18.6 Bn(p.219)
- • Powder Mixing Equipment market in India expected to grow 7% CAGR (FY2024-2029) from INR 32.8 Bn to INR 45.9 Bn(p.211)
- • Reactors and Storage Tanks market in India projected to grow 6.7% CAGR (FY2024-2029) to INR 95.1 Bn(p.230)
- • Government support through PLI scheme for pharmaceutical APIs and chemical sector expansion(p.207)
- • Hyderabad accounts for 40% of Indian bulk drug production and is designated as Pharma Hub(p.204)
- • Expansion into adjacent product segments and services(p.408)
- • Growing international market presence(p.408)
- • Leverage existing manufacturing infrastructure for capacity expansion(p.394)
- • Strategic acquisition and consolidation in the sector(p.388)
- • Indian pharmaceutical capex expected to remain at ₹120-150 billion per year till Fiscal 2027; government PLI policy supporting India as world pharmacy(p.449)
- • Indian chemical sector capex predicted to increase 7-9% CAGR until FY2025-26, reaching ₹70 Bn per year(p.449)
- • Partnerships with HHV Pumps, Asahi Glassplant Inc, GL Hakko strengthen position in glass lining and vacuum pumps markets(p.447)
- • Exclusive collaboration with GL Hakko for manufacturing and selling shell and heat tube exchangers in India and abroad except Japan(p.447)
- • Pan-India sales and distribution network with presence in multiple states and agency arrangements for Bangladesh, Russia and resale arrangements globally(p.446)
- • Strategic expansion into PTFE lined equipment manufacturing(p.467)
- • Growth in maintenance and service contracts business(p.469)
- • Potential capacity and production expansion(p.469)
- • Growing high-margin services revenue stream(p.467)
Threats
- • Geographic and political risks in Telangana state(p.33)
- • Pharma and chemical sector sensitivity to cyclical demand and capex(p.33)
- • Lack of long-term and exclusive customer/supplier contracts(p.33)
- • Customer payment delays and working capital requirements(p.34)
- • Disruption risks from industrial accidents, power failures and natural disasters at concentrated facilities(p.63)
- • Pharmaceutical sector facing compliance challenges and export declines(p.95)
- • Chemical sector experiencing slowdown with overcapacity and reduced export demand(p.96)
- • Heavy reliance on Indian domestic market creates concentration risk(p.77)
- • Dependence on skilled labour with no unionization protection against future disputes(p.63)
- • High dependence on electricity and water supply with power cuts occurring(p.75)
- • Exclusivity clauses restrict ability to sell products in major geographies(p.79)
- • Import dependence creates vulnerability to trade policy changes and currency fluctuations(p.86)
- • Interest rate sensitivity from variable rate borrowings and financing arrangements(p.71)
- • Declining attrition rate and high employee turnover challenges(p.66)
- • Market volatility and trading price uncertainty post-IPO listing(p.109)
- • Risk of listing failure or trading delays(p.109)
- • Regulatory and foreign exchange risks affecting operations(p.110)
- • Dependence on Indian market and regulatory environment(p.110)
- • Heavy dependence on pharmaceutical and chemical sector demand which is cyclical and subject to regulatory changes(p.71)
- • Intense competition from established players like GMM Pfaudler (33.3% market share) and HLE Glascoat (25.4%)(p.221)
- • Exposure to raw material price volatility and supply chain disruptions(p.80)
- • Regulatory and compliance risks in pharmaceutical and chemical manufacturing sectors(p.80)
- • Currency fluctuation risk given export exposure(p.80)
- • Global economic slowdown or recession could reduce capex spending by customers(p.80)
- • Pharmaceutical industry cyclicality and demand volatility(p.386)
- • Rising raw material and operating costs(p.408)
- • Intense competition from established and new market entrants(p.390)
- • Foreign exchange volatility affecting export competitiveness(p.410)
- • Regulatory and compliance requirements in pharmaceutical sector(p.358)
- • Macroeconomic factors affecting pharma and chemicals sectors including health concerns, pandemics, regulatory oversight, interest rates and government policies(p.449)
- • Raw material cost and availability volatility; dependence on commodity prices for stainless steel, carbon/mild steel, nickel alloy and other materials(p.450)
- • Risk of unanticipated delays, cost overruns in capital expenditure for expansion of manufacturing capacities(p.451)
- • Intense competition from organized and unorganized manufacturers and international competitors with greater financial and technological resources(p.452)
- • Changes in government regulations, policies, import duties and tariffs affecting manufacturing, safety, environmental protection and raw material sourcing(p.452)
- • Raw material price volatility and commodity exposure(p.475)
- • Interest rate risk on floating rate borrowings(p.475)
- • Foreign currency exchange risk(p.475)
- • Intensifying competitive conditions(p.477)
- • Inflation and macroeconomic uncertainty(p.476)
Promoters
| Name | Role | Pre-Issue | Post-Issue |
|---|---|---|---|
| Nageswara Rao Kandula | Promoter | 4.15% | — |
| Kandula Krishna Veni | Promoter | 21.45% | — |
| Kandula Ramakrishna | Promoter | 25.44% | — |
| Venkata Mohana Rao Katragadda | Promoter | 0.98% | — |
| Kudaravalli Punna Rao | Promoter | 0.27% | — |
| M/s S2 Engineering Services | Promoter | 13.02% | — |
| Nageswara Rao Kandula | Promoter | — | — |
| Kandula Krishna Veni | Promoter | — | — |
| M/s S2 Engineering Services | Promoter | — | — |
| Kandula Ramakrishna | Promoter | 25.44% | — |
| Kandula Krishna Veni | Promoter | 21.45% | — |
| M/s S2 Engineering Services | Promoter | 13.02% | — |
| Nageswara Rao Kandula | Promoter | 4.15% | — |
| M/s Standard Holdings | Promoter Group | 2.73% | — |
| Asahi Glassplant INC. | Investor | — | — |
| GL Hakko Co., Ltd | Investor | — | — |
| Monoform Management Support Co., Ltd | Investor | — | — |
| Not stated in this document section | Promoter | — | — |
| Nageswara Rao Kandula | Promoter | — | — |
| Kandula Krishna Veni | Promoter | — | — |
| Kandula Ramakrishna | Promoter | — | — |
| M/s S2 Engineering Services | Promoter Group | — | — |
| Nageswara Rao Kandula | Promoter/Managing Director | 4.21% | — |
| Kandula Krishna Veni | Promoter/Executive Director | 22.74% | — |
| Kandula Ramakrishna | Promoter/Executive Director | 26.96% | — |
| Kudaravalli Punna Rao | Promoter | 0.28% | — |
| Venkata Mohana Rao Katragadda | Promoter/Executive Director | 0.99% | — |
| M/s S2 Engineering Services | Promoter Group | 13.23% | — |
| M/s S2 Engineering Services | Promoter | — | — |
| Kandula Ramakrishna | Promoter | — | — |
| Kandula Krishna Veni | Promoter | — | — |
| Nageswara Rao Kandula | Promoter | — | — |
| Kudaravalli Punna Rao | Promoter | — | — |
| Nageswara Rao Kandula | Promoter | — | — |
| Kandula Krishna Veni | Promoter | — | — |
| Kandula Ramakrishna | Promoter | — | — |
| Kudaravalli Punna Rao | Promoter | — | — |
| Venkata Mohana Rao Kataragadda | Promoter | — | — |
| M/s S2 Engineering Services | Promoter | — | — |
Leadership
Nageswara Rao Kandula · Managing Director
Sambasiva Rao Gollapudi · Chairman (Non-Executive, Independent Director)
Kandula Ramakrishna · Director
Kandula Krishna Veni · Director
Venkata Mohana Rao Katragadda · Director
Kallam Hima Priya · Company Secretary and Compliance Officer
Pathuri Anjaneyulu · Chief Financial Officer
Auto-extracted from the company's RHP using AI, with each fact linked to its source passage (hover any row to see the quote & page). Provided for research only, not investment advice — verify against the official RHP before relying on it.
Standard Glass Lining Technology IPO FAQs
What is the lot size of Standard Glass Lining Technology IPO?
The minimum lot size of Standard Glass Lining Technology IPO is 107 shares. One lot costs ₹14,980 at the cut-off price.
When does Standard Glass Lining Technology IPO open and close?
Standard Glass Lining Technology IPO opened for subscription on 06 Jan 2025 and closed on 08 Jan 2025.
What is the listing date of Standard Glass Lining Technology IPO?
Standard Glass Lining Technology IPO listed on 13 Jan 2025.